EXHIBIT (99.1) Revised Selected Financial Data
The information required by this item is incorporated by reference to Note 1 and Note 12 to our Consolidated Financial Statements.
Financial Summary (Unaudited)
Amounts in millions, except per share amounts | 2015 (2) | 2014 | 2013 | 2012 | 2011 | 2010 | |||||||||||||||||
Net sales | $ | 70,749 | $ | 74,401 | $ | 73,910 | $ | 73,138 | $ | 70,464 | $ | 66,810 | |||||||||||
Gross profit | 33,693 | 35,371 | 35,858 | 35,254 | 35,110 | 34,263 | |||||||||||||||||
Operating income | 11,049 | 13,910 | 13,051 | 12,495 | 13,849 | 14,001 | |||||||||||||||||
Net earnings from continuing operations | 8,287 | 10,658 | 10,346 | 8,864 | 10,509 | 9,635 | |||||||||||||||||
Net earnings/(loss) from discontinued operations | (1,143 | ) | 1,127 | 1,056 | 2,040 | 1,418 | 3,211 | ||||||||||||||||
Net earnings attributable to Procter & Gamble | 7,036 | 11,643 | 11,312 | 10,756 | 11,797 | 12,736 | |||||||||||||||||
Net earnings margin from continuing operations | 11.7 | % | 14.3 | % | 14.0 | % | 12.1 | % | 14.9 | % | 14.4 | % | |||||||||||
Basic net earnings per common share: (1) | |||||||||||||||||||||||
Earnings from continuing operations | $ | 2.92 | $ | 3.78 | $ | 3.65 | $ | 3.08 | $ | 3.62 | $ | 3.21 | |||||||||||
Earnings/(loss) from discontinued operations | (0.42 | ) | 0.41 | 0.39 | 0.74 | 0.50 | 1.11 | ||||||||||||||||
Basic net earnings per common share | $ | 2.50 | $ | 4.19 | $ | 4.04 | $ | 3.82 | $ | 4.12 | $ | 4.32 | |||||||||||
Diluted net earnings per common share: (1) | |||||||||||||||||||||||
Earnings from continuing operations | $ | 2.84 | $ | 3.63 | $ | 3.50 | $ | 2.97 | $ | 3.46 | $ | 3.08 | |||||||||||
Earnings/(loss) from discontinued operations | (0.40 | ) | 0.38 | 0.36 | 0.69 | 0.47 | 1.03 | ||||||||||||||||
Diluted net earnings per common share | $ | 2.44 | $ | 4.01 | $ | 3.86 | $ | 3.66 | $ | 3.93 | $ | 4.11 | |||||||||||
Dividends per common share | $ | 2.59 | $ | 2.45 | $ | 2.29 | $ | 2.14 | $ | 1.97 | $ | 1.80 | |||||||||||
Research and development expense | $ | 1,991 | $ | 1,910 | $ | 1,867 | $ | 1,874 | $ | 1,812 | $ | 1,733 | |||||||||||
Advertising expense | 7,180 | 7,867 | 8,188 | 7,839 | 7,713 | 7,060 | |||||||||||||||||
Total assets | 129,495 | 144,266 | 139,263 | 132,244 | 138,354 | 128,172 | |||||||||||||||||
Capital expenditures | 3,736 | 3,848 | 4,008 | 3,964 | 3,306 | 3,067 | |||||||||||||||||
Long-term debt | 18,327 | 19,807 | 19,111 | 21,080 | 22,033 | 21,360 | |||||||||||||||||
Shareholders' equity | 63,050 | 69,976 | 68,709 | 64,035 | 68,001 | 61,439 |
(1) | Basic net earnings per common share and diluted net earnings per common share are calculated based on net earnings attributable to Procter & Gamble. |
(2) | Our 2015 net sales were negatively impacted by approximately $4.4 billion of unfavorable foreign exchange fluctuation compared to 2014. Net earnings attributable to Procter & Gamble in 2015 were negatively impacted by approximately $1.4 billion due to foreign exchange, $2.1 billion of non-cash impairment charges related to the Batteries business reported in discontinued operations and a $2.1 billion Venezuelan deconsolidation charge. These impacts are discussed more fully in "Summary of 2015 Results" and "Results of Operations" of the MD&A (Exhibit 99.2). |